Evidence map›Paper›PMID 40864052›Full record

ArticleToxins2025

A Novel Anti-BoNT/A Neutralizing Antibody Possessed Overlapped Epitope with SV2 and Had Prolonged Half-Life In Vivo.

Shangde Peng, Naijing Hu, Fenghao Peng, Huirong Mu, Zihan Yi, Cong Xing, Liang Zhang, Wen Hu, Xinyi Zhou, Yan Wen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shangde PengCollege of Biotechnology, Campus of Jiangsu University of Science and Technology, Zhenjiang 212100, China.
Naijing HuState Key Laboratory of National Security Sepcially Needed Medicines, Beijing 100039, China.ORCID 0000-0003-2659-6837
Fenghao PengState Key Laboratory of National Security Sepcially Needed Medicines, Beijing 100039, China.
Huirong MuCollege of Biotechnology, Campus of Jiangsu University of Science and Technology, Zhenjiang 212100, China.
Zihan YiCollege of Biotechnology, Campus of Jiangsu University of Science and Technology, Zhenjiang 212100, China.
Cong XingJoint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China.
Liang ZhangCollege of Biotechnology, Campus of Jiangsu University of Science and Technology, Zhenjiang 212100, China.
Wen HuCollege of Biotechnology, Campus of Jiangsu University of Science and Technology, Zhenjiang 212100, China.
Xinyi ZhouCollege of Biotechnology, Campus of Jiangsu University of Science and Technology, Zhenjiang 212100, China.
Yan WenCollege of Biotechnology, Campus of Jiangsu University of Science and Technology, Zhenjiang 212100, China.
Jiannan FengState Key Laboratory of National Security Sepcially Needed Medicines, Beijing 100039, China.
Chunxia QiaoState Key Laboratory of National Security Sepcially Needed Medicines, Beijing 100039, China.

Funding

Jiangsu Province Graduate Research and Practice Innovation Program Project KYCX24_4149National Natural Sciences Foundation of China 31070820
6 · The paper itself

Abstract

The C-terminus of the BoNT/A heavy chain (BoNT/AHC) mediates binding to its receptor, SV2, a critical step for toxicity. Antibody inhibition of this interaction enhances neuronal survival. We previously identified a functional anti-BoNT/AHC nanobody, HM. To extend its in vivo half-life, we designed and prepared two Fc-optimized nanoparticles, HM-Fc5 and HM-Fc6. Structural modeling (homology/docking) of the HM Fv-AHC complex predicted that HM engages key AHC residues (Tyr

Indexed as

Antibodies, NeutralizingEpitopesSingle-Domain AntibodiesAnimalsFemaleHalf-LifeHumansMaleMiceNanoparticlesAntibodies, NeutralizingEpitopesSingle-Domain AntibodiesBoNT/AHCFcRnhalf-lifenanobodySV2

Identifiers

PMID40864052
PMCPMC12390173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.